**Neovascular Age-Related Macular Degeneration (nAMD)** is an eye condition that causes vision loss. This study tests a new treatment, **AR-14034**, to see if it's safe and lasts long. **Stage 1** lasts 48 weeks. It involves 10 people who already received other eye treatments. They will visit the clinic to check safety and early effects. **Stage 2** lasts 56 weeks, with 130 people. They will be split into groups, receiving different doses of AR-14034 or a comparison drug called **aflibercept**. This stage includes a 16-week extension to further assess treatment. Participants must have certain vision levels and be able to give consent. They should not have other eye diseases or uncontrolled health conditions. Pregnant women, or those planning to become pregnant, cannot participate. **Key Points:**

• **Length and Visits:** Stage 1 is 48 weeks, and Stage 2 is 56 weeks with a 16-week extension, requiring regular clinic visits.
• **Eligibility:** Participants need specific vision levels and cannot have certain health issues.
• **Risks and Considerations:** Women who are pregnant or planning to be should not participate.